Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis

European Journal of Neurology

Volumn 20, Issue 7, 2013, Pages 1032-1042

  Grove, R A ^a   Shackelford, S ^b   Sopper, S ^c   Pirruccello, S ^d   Horrigan, J ^b   Havrdova, E ^e   Gold, M ^b   Graff, O ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d NEBRASKA MEDICAL CENTER   (United States)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Firategrast; Integrin antagonists; Lymphocytes; Multiple sclerosis; Progressive multifocal leukoencephalopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; FIRATEGRAST; PLACEBO;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; CD4 CD8 RATIO; CEREBROSPINAL FLUID ANALYSIS; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSURVEILLANCE; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; QUANTITATIVE ANALYSIS; SIDE EFFECT; SUBARACHNOID SPACE; T LYMPHOCYTE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRINS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME;

EID: 84879022800     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12097     Document Type: Article

References (26)

1. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294. [Erratum, Ann Neurol 1996; 40: 480.]
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504. [Erratum, Lancet 1999; 353: 678].
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
5. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178. [Erratum, Neurology 2002; 59: 480].
6. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
7. Rudick RA, Stuart WH, Calabresi PA, et al. A randomized, placebo-controlled trial of natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
8. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59: 743-747.
9. de Graff M, Smitt P, Luitwieler R, et al. Central memory CD4+ T cells dominate the normal cerebrospinal fluid. Cytometry B Clin Cytom 2011; 80B: 43-50.
10. Matusi M, Araya S, Wang H, Matsushima K, Saida T. Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis. J Neurol 2005; 252: 908-915.
11. Petereit H, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells, and intrathecal IgG synthesis. Acta Neurol Scand 2008; 117: 399-403.
12. Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006; 63: 1383-1387.
13. Allavena R, Noy S, Andrews M, Pullen N. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010; 176: 556-562.
14. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-[alpha]4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466-472.
15. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
16. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
17. Miller DH, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double blind, placebo controlled trial. Lancet Neurol 2012; 11: 2-131.
18. Sutherland DR, Anderson L, Keeney M, Nayar R, Chine-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hemotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
19. Kurtze JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
20. Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72: 396-401.
21. Mareckova H, Havrdova E, Krasulova E, Vankova Z, Koberova M, Sterzl I. Natalizumab in the treatment of patients with multiple sclerosis - first experience. Ann N Y Acad Sci 2007; 1110: 465-473.
22. Poopatana CA, Chowdhury S, Barrett KV, Dinzey J, Sadiq SA. Monitoring of natalizumab therapy with cerebrospinal fluid activation markers. Poster 495. Mult Scler 2008; 14(Suppl. 1): S174.
23. Bonig H, Wundes A, Chang K, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439-3441.
24. Zohren F, Toutzaris D, Klarner V, Hartup HP, Kieseier B, Haas R. The monoclonal anti VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893-3895.
25. Hickey WF. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001; 36: 118-124.
26. Kivisakk P, Imitola J, Rasmussen S, et al. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 2009; 65: 457-469.